|12th October 2020||Jin Long Chen||25,000||Open or private sale||$17.02||$425,500.00|
|22nd September 2020||Peter Svennilson||608,000||Open or private sale||$30.85||$18,756,800.00|
|2nd September 2020||Group L P Column||27,595||Open or private purchase||$17.67||$487,603.65|
|1st September 2020||Jin Long Chen||7,613||Open or private sale||$18.32||$139,470.16|
|1st September 2020||Jin Long Chen||17,387||Open or private sale||$17.62||$306,358.94|
|1st September 2020||Group L P Column||36,494||Open or private purchase||$17.64||$643,754.16|
|28th August 2020||Group L P Column||26,135||Open or private purchase||$17.89||$467,555.15|
|27th August 2020||Group L P Column||36,359||Open or private purchase||$17.79||$646,826.61|
|25th August 2020||Group L P Column||100||Open or private purchase||$18.00||$1,800.00|
|24th August 2020||Group L P Column||11,024||Open or private purchase||$17.96||$197,991.04|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity and oncology.